ACCEPATION OF ADD SOON

P28506.P01	<u> </u>	NUMBER OF STREET
Form PTO-1390	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER P28506
" TRANSMITTAL LETTER TO	THE UNITED STATES	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)
DESIGNATED/ELECTED CONCERNING A FILING U	OFFICE (DO/EO/US)	10/550,013
INTERNATIONAL APPLICATION NO. PCT/EP2003/013008	INTERNATIONAL FILING DATE 20 November 2003	PRIORITY DATE CLAIMED 24 March 2003
TITLE OF INVENTION USE OF 5-SUBSTITUTED NUCLEOSIDES FOR REINFORCING THE APOPTOTIC EFFECT OF CYTOSTATIC DRUGS		
APPLICANT(S) FOR DO/EO/US Rudolf FAHRIG, Joerg-Christian HEINRICH, and Georg KRUPITZA		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information.		
1. This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.		
2. A This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.		
3. This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (23) indicated below.		
4. The US has been elected (PCT Article 31).		
 5. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. is attached hereto (required only if not communicated by the International Bureau). b. has been communicated by the International Bureau. c. is not required, as the application was filed in the United States Receiving Office (RO/US). 		
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2)). a. ☐ is attached hereto. b. ☐ has been previously submitted under 35 U.S.C. 154 (d) (4).		
7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))		
a. are attached hereto (required only if not communicated by the International Bureau). b. have been communicated by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made.		
8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).		
9. 🛮 An oath or declaration of the inventor(s) (35 U.S.C371(c)(4)).		
"Executed"		
10. An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).		
Items 11 to 22 below concern other document(s) or information included:		
11. Assignee: RESprotect GmbH, of Dresden, German		
12. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.		
13. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.		
 14. ☐ A FIRST preliminary amendment. ☑ A SECOND or SUBSEQUENT preliminary amendment. 		
15. An Application Data Sheet under 37 C.F.R. 1.76.		
16. A substitute specification.		
17. A power of attorney and/or change of address letter.		
18. Figure of Drawing to be published: 1		
19. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825.		
20. A second copy of the published international application under 35 U.S.C. 154 (d) (4).		
21. A second copy of the English language translation of the international of the international application under 35 U.S.C. 154 (d) (4).		
22. Other items or information: Cover Letter .		

REGISTRATION NUMBER

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: R. FAHRIG et al. Mail Stop PCT

PCT Branch

Appl. No.: 10/550,013

(National Stage of PCT/ PCT/EP2003/013008)

I. A. Filed : 20 November 2003

For : USE OF 5-SUBSTITUTED NUCLEOSIDES FOR REINFORCING THE

APOPTOTIC EFFECT OF CYTOSTATIC DRUGS

COVER LETTER

Mail Stop PCT

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop PCT
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

In order to comply with the requirements for the submission of an executed Declaration in the above-identified application, and prior to receipt of the Notification which should set a time limit for submission of materials, and further to the filing of the above-identified application and the filing fee on September 23, 2005. Applicant hereby submits:

- Transmittal Letter to the United States Designated/Elected Office Concerning a
 Filing Under 35 U.S.C. 371;
- an executed Declaration and Power of Attorney;
- Supplemental Preliminary Amendment;
- a check in the amount of \$130.00 to cover the surcharge for late filing of the
 Declaration.

1

P28506

The U.S. Patent and Trademark Office is hereby authorized to charge any additional fees or credit any overpayment to Deposit Account No. 19-0089.

Should the Examiner have any questions, the Examiner is invited to contact the undersigned at the below-listed number.

Respectfully submitted, R. FAHRIG et al.

Neil F. Greenblum

Reg. No. 28,394

April 3, 2006 GREENBLUM & BERNSTEIN, P.L.C. 1950 Roland Clarke Place Reston, VA 20191 (703) 716-1191